BioMarin Pharmaceutical lowers FY2026 adjusted EPS and sales guidance

BioMarin Pharmaceutical lowered its FY2026 adjusted EPS guidance from $4.90-$5.10 to $2.80-$3.10, versus the $3.32 estimate, and cut FY2026 sales guidance from $3.875B-$3.925B to $3.800B-$3.900B, versus the $3.918B estimate.

Detected & updated continuously · Source: Nebula